Janux Therapeutics (JANX) Fundamental Analysis: Revenue, Earnings & Valuation

7.15 / 10

Outperform

Fundamentally, JANX is rated Outperform with a 7.2/10 quality score. Strengths include a low current‑liabilities‑to‑total‑liabilities ratio (55.9%), strong interest coverage (35.1x), and positive asset‑to‑market‑value signals. Revenue growth is negative, but cost structure remains moderate.

Analysis Checks(10/10)

Revenue-MV

Value-0.11

Score3/3

Weight29.66%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value-5.55

Score2/3

Weight0.41%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-3.38%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value55.87

Score2/3

Weight1.15%

1M Return0.36%

PB-ROE

Value-0.25

Score2/3

Weight27.67%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value0.02

Score2/3

Weight-1.05%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.44%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-5.55

Score2/3

Weight0.16%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-3.25%

1M Return-1.13%

Asset-MV

Value-0.55

Score3/3

Weight52.07%

1M Return11.61%

Is JANX undervalued or overvalued?

JANX scores 7.15/10 on fundamentals and holds a Discounted valuation at present. Backed by its -11.48% ROE, -1136.25% net margin, -7.44 P/E ratio, 0.88 P/B ratio, and -42.97% earnings growth, these metrics solidify its Outperform investment rating.